The FDA accepts Biogen's (BIIB) application for the approval of the company's Recombinant FIXFc...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

The FDA accepts Biogen's (BIIB) application for the approval of the company's Recombinant FIXFc clotting drug to treat hemophilia B and grants a standard review timeline. Biogen says Recombinant FIXFc will allow less frequent injections for patients and cut bleeding rates. (PR)